Regulatory Compliance

New York – September 21, 2026 -- Hartree Partners has agreed to purchase and market approximately 10,000 metric tons per year of lithium carbonate from Bridge Green Upcycle under an eight-year commercial agreement valued at an estimated $500 million to $1 billion at current market conditions.

Hartree secures exclusive marketing rights across all lithium carbonate grades produced at Bridge Green facilities

The agreement grants Hartree exclusive marketing rights for lithium carbonate produced by Bridge Green during the initial term, with an option to renew for an additional seven years. Hartree also made an equity investment in Bridge Green's bridge financing round, funding the company's planned expansion of battery recycling and critical-mineral refining. First lithium carbonate volumes under the agreement are projected for 2028.

New York – September 21, 2026 -- FADEL and Gournay Consulting have launched a new connector integrating Bynder's digital asset management platform with FADEL Brand Vision, adding rights intelligence and AI-powered content tracking to brand compliance workflows.

Connector links Bynder's asset library to FADEL's rights and compliance engine

Built by Gournay Consulting, a premier Bynder partner, the integration keeps Bynder as the system of record for managing and distributing digital assets while FADEL Brand Vision supplies usage rights, restrictions, and expiration data tied to each asset. Users can validate rights clearance for a specific timeframe, format, and territory without leaving the Bynder interface.

Idaho Falls – September 21, 2026 -- Construction projects in Eastern Idaho frequently require a stack of approvals beyond the standard building permit, including well permits, septic system reviews, driveway access clearances, utility connection permits, and floodplain reviews, according to insights from Ren Ferguson of Copper Creek Homes published by HelloNation.

Rural properties depend on private well and septic approvals instead of municipal utilities

Many properties across Eastern Idaho rely on private water and wastewater systems rather than city infrastructure. A well permit confirms proper placement and water quality, while septic system approval requires soil evaluations and detailed site plans reviewed by local health districts before foundation work can proceed.

Chicago and Lyon – September 21, 2026 -- Mérieux NutriSciences has secured Peugeot Invest and Continental Grain Company (Conti) as new strategic minority shareholders to help finance its acquisition of Certified Group, a North American testing, inspection and certification (TIC) operator generating approximately $300 million in revenue.

Certified Group deal adds 31 laboratories across North America

The acquisition expands Mérieux NutriSciences' footprint in the world's largest food TIC market, which the company estimates at more than $2.5 billion for outsourced services. Certified Group's network brings capabilities in animal protein, dairy and packaged foods, alongside adjacent sectors including cosmetics, health supplements, over-the-counter drugs and reduced-harm nicotine products.

Steamboat Springs, Colo. – September 21, 2026 -- ElektraFi has deployed broadband infrastructure across Routt and Moffat Counties, delivering high-reliability internet to areas that federal and state programs have consistently failed to reach.

Colorado's Middle Mile Program allocated zero funding to two counties with documented connectivity gaps

The Colorado Broadband Office's recent Middle Mile Program awards excluded Routt and Moffat Counties entirely, despite acknowledged service shortfalls in the region. ElektraFi's network already reaches critical governmental and public agencies ahead of any public capital deployment, including Yampa Valley Regional Airport, the Steamboat Springs Fire Station, and the local Water Treatment Plant.

Providence, R.I. – September 21, 2026 -- Nabsys 2.0, LLC has published the first study combining CRISPR/Cas9 with its proprietary Electronic Genome Mapping (EGM) technology, demonstrating a method to both evaluate CRISPR/Cas9 activity and direct EGM to target specific genomic regions rather than only genome-wide analysis.

The preprint, titled 'CRISPR/Cas9 Optimization Using Electronic Genome Mapping: Potential Role for Studying Human Genetic Disease,' was led by John F. Thompson, Ph.D., Principal Application Scientist at Nabsys, and posted on bioRxiv.

Beijing – September 21, 2026 -- T-MAXIMUM Pharmaceutical reported that two of three evaluable patients with refractory brain metastases from lung cancer achieved partial responses with roughly 80% tumor shrinkage after treatment with its allogeneic B7-H3-targeted CAR-T therapy, MT027, according to early data presented at the IASLC World Conference on Lung Cancer (WCLC 2026) in Seoul.

Two of three evaluable patients hit 80% tumor shrinkage in dose-escalation trial

In the prospective, investigator-initiated trial (ChiCTR2500107346), five patients with heavily pretreated, guideline-exhausted brain metastases completed treatment. Of the three with measurable disease, two achieved partial responses and one achieved stable disease. As of the company's September 2026 follow-up, the two responders have survived more than 11 and 13 months, respectively, since their first MT027 dose, and all three evaluable patients remain alive.

Jerusalem – September 21, 2026 -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) has regained compliance with Nasdaq's $1.00 minimum bid price rule after its American Depositary Shares closed at or above that threshold for 19 consecutive business days, Nasdaq Listing Qualifications confirmed in a September 18, 2026 letter.

Nasdaq closes compliance matter after ADS price clears threshold for 19 sessions

The closing bid price of Scinai's ADSs met or exceeded $1.00 per share from August 21, 2026 through September 17, 2026, satisfying Nasdaq Listing Rule 5550(a)(2). Nasdaq had first flagged the deficiency on March 12, 2026, after the ADSs failed to maintain the $1.00 minimum over the prior 30 consecutive business days.

CEO says resolution shifts focus to CDMO commercial execution

"Receiving Nasdaq's confirmation closes an important compliance matter for Scinai,

Bridgewater, N.J. – September 21, 2026 -- The U.S. Food and Drug Administration has accepted Insmed Incorporated's supplemental New Drug Application (sNDA) for full approval of ARIKAYCE (amikacin liposome inhalation suspension) to treat Mycobacterium avium complex (MAC) lung disease, granting Priority Review with a PDUFA target action date of January 28, 2027.

FDA sets January 28, 2027 decision date under Priority Review

The Priority Review designation applies to therapies that could offer significant improvement in safety or efficacy for serious conditions. Insmed said full approval would allow ARIKAYCE, administered via PARI Pharma's Lamira Nebulizer System, to reach patients earlier in their disease course, including newly diagnosed cases and those with recurrent infections.

Germantown, Md. – September 21, 2026 -- The U.S. Food and Drug Administration has granted platform technology designation to Precigen's AdenoVerse immunotherapeutic platform, the technology underlying the company's first commercial product, PAPZIMEOS, approved in August 2025 for recurrent respiratory papillomatosis (RRP) in adults.

FDA designation opens accelerated pathway for future AdenoVerse cancer programs

The designation allows Precigen to leverage manufacturing and preclinical data generated for PAPZIMEOS to support future marketing applications for other AdenoVerse-based candidates, reducing duplicative development work. It also grants the company earlier and more frequent FDA engagement and allows regulators to consider prior manufacturing inspections when reviewing future applications.